Single-point and kinetics of peripheral residual disease by mass spectrometry to predict outcome in patients with high risk smoldering multiple myeloma included in the GEM-CESAR trial
The value of quantitative immunoprecipitation mass spectrometry (QIP-MS) to identify the M-protein is being investigated in patients with monoclonal gammopathies but no data are yet available in high-risk smoldering myeloma (HRsMM). We have therefore investigated QIP-MS to monitor peripheral residu...
Salvato in:
| Autori principali: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Ferrata Storti Foundation
2024-07-01
|
| Serie: | Haematologica |
| Accesso online: | https://haematologica.org/article/view/11683 |
| Tags: |
Nessun Tag, puoi essere il primo ad aggiungerne!!
|
